Japanese Prostate Cancer Imaging Trial Meets Study Objectives
February 07, 2022 18:08 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
January 27, 2022 16:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
January 26, 2022 16:51 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA
January 25, 2022 01:29 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Raphaël Ortiz has joined the Company...
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
December 21, 2021 19:49 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
December 20, 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
December 19, 2021 16:47 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
December 07, 2021 17:42 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
Illuccix® recebe autorização de uso de imagens de câncer de próstata no Brasil
November 30, 2021 19:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Austrália e PORTO ALEGRE, Brasil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- A Telix Pharmaceuticals Limited (ASX: TLX, Telix, a Empresa) anunciou hoje que a Agência Nacional de Vigilância...
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
November 30, 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and PORTO ALEGRE, Brazil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory...